PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

RPS calls for prevention of counterfeit medicines in UK’s supply chain

The Royal Pharmaceutical Society of Great Britain (RPS) has called on the UK government to take immediate action to fight counterfeit medicines from entering the country following the UK’s exit from the European Union.

The RPS, in a letter addressed to Health Secretary Matt Hancock, emphasised the need for rigorous plans to be put in place to maintain formal links with the EU. This will help to authenticate the legitimacy of medicines that move between the EU and the UK.

Under current plans, the UK will cease to benefit from the provisions of the Falsified Medicines Directive (FMD). This ensures that medicines in the EU are legitimate, safe and high-quality.

The RPS has presented concerns that this could leave the UK vulnerable to a swarm of counterfeit medicine entering the supply chain, which could impact patient care in the UK and across the EU.

“In our letter to the Government we have emphasised that establishing technical agreements with the EU is now more critical than ever in our fight against counterfeit medicines. We have made it clear that the ideal way forward is for continuity of the provisions of the Falsified Medicines Directive, enabling ongoing connectivity between the UK and Europe,” said Sandra Gidley, president of the RPS.

“Not only will this help to provide assurances to patients about the safety of their medicines but it will also ensure the UK can continue to benefit from the significant investment made by the NHS, pharmacy organisations and individual pharmacy owners in the infrastructure for FMD,” she added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026